A grand welcome to all the experts and researchers from globally to attend our “International Conference and Expo on Drug Discovery and Drug Development” which is scheduled during June 10-11, 2023 at Singapore
The Conference will tremendously reflect the current trends, new strategies, recent advances, new approaches and future trends in Drug Discovery and Drug Development which deals with the number of processes like target identification and validation, lead identification, lead generation and optimization and finally the identification of a candidate for further development. Drug Development, on the other hand, includes optimization of chemical synthesis and its formulation, toxicological and adverse effects.
Drug discovery is the process through which novel candidate pharmaceuticals are found in the domains of medicie, biotechnology, and pharmacology. Historically, the active component in medications was isolated from conventional treatments or found by serendipitous discovery.
Following the identification of a lead molecule through the process of drug discovery. Drug Development is the process of bringing a novel pharmaceutical medicine to market. Preclinical research on microorganisms and animals is a part of this process, as is applying for regulatory status with agencies like the US Food and Drug Administration for an investigational new drug in order to start human clinical trials. It may also include the step of obtaining regulatory approval with a new drug application in order to market the drug. It normally takes more than ten years for a vaccine or medication to be authorised, from idea to preclinical testing in the lab to clinical trial development, including Phase I-III trials.
Hilaris Conferences is hosting the International Conferences, leading worldwide researchers, scientists, academic scientists, industry researchers, doctors, practitioners and other professionals to gather in Drug Discovery 2023. We heartily invites you to take part for the Hilaris Conferences and share your research for a Great future ".
Why to Attend..?
International conference and expo on drug discovery and drug development will provide great opportunities for you to communicate your research to a wide and interested audience, get feedback on your projects and research works , learn from other speakers and senior scientists and that broaden your professional network and your scientific knowledge .
Attending conferences on drug discovery with other drug hunters is a great opportunity to stay up-to-date, increase your knowledge base in drug discovery, and discover ideas for future projects and research works . Interacting with other passionate and senior drug discovery leaders attending these conferences a great way to grow your expertise and network.
The terminal goal of drug development is to bring a new compound without any adverse and toxicity effects and with great therapeutic effect to the market. In this state of affairs the transition from preclinical research to clinical phases marks a critical turning point, as it nears the new medicinal product to the market
TARGETED AUDIENCE
Scientists
Clinical Researchers
Chemists and Drugists
Scientists related to R&D
Microbiologists
Pharmaceuticals
ResearchOrganizations
Research and Development departments
Pharmacovigilance Department
Vaccine Developers
Vaccine Investigators
Vaccine Manufacturing Companies
University Faculty
Medical Schools/Colleges
Students
With Pride and Privilege, Hilaris conference invites all the experts and researchers from globally to attend our “International Conference and Expo on Drug Discovery and Drug Development” with the theme “Research and Brand new strategies on In Vivo, In Vitro and In Silico Drug Discovery and Drug Development” and it was take place during June 10-11, 2023 at Singapore Drug Discovery 2023 will tremendously reflect the current trends, new strategies, recent advances, new approaches and future trends in Drug Discovery and Drug Development
MARKETED ANALYSIS:
The drug discovery market is anticipated to listing a CAGR of nearly 8.21% during the predicted period, with a revenue of nearly USD 58,324.97 million in 2021. It is expected to outreach 91,107.71 million by 2027. The COVID-19 widespread , countries' health systems are promptly investing in R&D to fight with the virus. Essential compounds were screened from the, ZINC, CHEMBL, FDA-approved drugs, and compounds under clinical trials.
According to (CVDs) Cardiovascular diseases major facts published by the World Health Organization (WHO) in June 2021, CVDs are the major cause of death throughout the world, representing around 32% of all worldwide deaths. Moreover, new plans are required to streamline and decrease the costs of clinical trials while placing more importance on the patient experience and voice.
By According to the American Cancer Society, in 2020, over 1.8 million new cancer cases were recognized to be diagnosed, and nearly 606,520 cancer deaths may have noted in the USA. Thus, the increasing affect of a wide range of diseases among all age groups and its affect, worldwide, drive the demand for drug discovery & development and its market.
MAJOR ASSOCIATION:
- Abbott Laboratories Inc.
- Agilent Technologies Inc.
- Eli Lilly and Company
- F. Hoffmann-La Roche Ltd
- GlaxoSmithKline PLC
- Merck & Co. Inc AstraZeneca PLC.
- Novartis
- Pfizer Inc.
- Bayer AG
- Shimadzu Corp.
- Takeda Pharmaceuticals
- Teva Pharmaceuticals
